<code id='D905C97935'></code><style id='D905C97935'></style>
    • <acronym id='D905C97935'></acronym>
      <center id='D905C97935'><center id='D905C97935'><tfoot id='D905C97935'></tfoot></center><abbr id='D905C97935'><dir id='D905C97935'><tfoot id='D905C97935'></tfoot><noframes id='D905C97935'>

    • <optgroup id='D905C97935'><strike id='D905C97935'><sup id='D905C97935'></sup></strike><code id='D905C97935'></code></optgroup>
        1. <b id='D905C97935'><label id='D905C97935'><select id='D905C97935'><dt id='D905C97935'><span id='D905C97935'></span></dt></select></label></b><u id='D905C97935'></u>
          <i id='D905C97935'><strike id='D905C97935'><tt id='D905C97935'><pre id='D905C97935'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:explore    Page View:412
          Blood samples
          Marion Berard/AFP/GettyImages

          With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is bracing for the crush.

          Based on their ability to slow cognitive decline, the Eisai/Biogen drug Leqembi won full approval from the FDA this month, and donanemab by Eli Lilly could be approved by year end. Clinicians now have to decide which patients are most suitable for treatment, which means better Alzheimer’s tests need to be developed.

          advertisement

          “There’s going to be capacity issues because there’s just not enough neurologists in the world to treat this pool of patients with Alzheimer’s disease at the moment,” said Mark Stearman, a senior international product manager at Roche focusing on Alzheimer’s diagnostics.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          ALS patient reclaims some autonomy thanks to wearable 'robot'
          ALS patient reclaims some autonomy thanks to wearable 'robot'

          AlexHogan/STATJohnGoodsonpracticedmedicineforalmost50yearsatMassachusettsGeneralHospitalinBoston.Asa

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Lilly's Alzheimer's drug donanemab backed by FDA advisers

          DarronCummings/APAdviserstotheFoodandDrugAdministrationvoted11-0onMondaytorecommendtheapprovalofadru